Glycogen synthesis is vital, malstructure resulting in precipitation and accumulation into neurotoxic polyglucosan bodies (PBs). One well-understood mechanism of PB generation is glycogen branching enzyme deficiency (GBED). Less understood is Lafora disease (LD), resulting from absence of the glycogen phosphatase laforin or the E3 ubiquitin ligase malin, and accumulation of hyperphosphorylated PBs. LD afforded first insight that glycogen sphericity depends on more than adequate branching activity. Unexpectedly, deficiencies of the Linear Ubiquitin Chain Assembly Complex (LUBAC) components RBCK1 and HOIP result in PBs in muscle tissues. Here we analyzed nervous system phenotypes of mice lacking RBCK1 and find profuse PB accumulations in brain and spinal cord with extensive neurodegeneration and neurobehavioral deficits. Brain glycogen in these mice is characterized by long chains and hyperphosphorylation, similar to LD. Like in LD, glycogen synthase and branching enzyme are unaltered. Regional PB distribution mirrors LD and not GBED. Perisynaptic PB localization is unlike LD or GBED. The results indicate that RBCK1 is part of a system supplementing laforin-malin in regulating glycogen architecture including in unique neuronal locales.
INTRODUCTION
Intracellular storage of blood-derived glucose in the form of highly branched glycogen molecules is critical for life, allowing large amounts of glucosyl residues to be stored in compact yet soluble particles. Crucial to glycogen's solubility is its relatively short chains and high abundance of evenly distributed branch points, preventing the chains from forming double helices and precipitating (which is the case in amylopectin, the major glucose storage molecule in plants). The principle enzymes involved in glycogen synthesis, glycogenin (GYG1, synthesis initiation), glycogen synthase (GYS1/GYS2, chain elongation) and glycogen branching enzyme (GBE1, branching) have been known for decades [1] [2] [3] . GBED (Glycogen Storage Disease IV; GSD IV) leads to a pathological accumulation of poorly branched insoluble glycogen, which precipitates and accumulates into PBs 4 . The age of onset and severity of GSD IV is determined by the amount of residual GBE1 activity. Near total absence of GBE1 results in the infantile Andersen's disease, a severe condition which leads to childhood liver failure and early fatality 5 . Conversely, mutations associated with higher residual GBE1 activity (most commonly in patients homozygous for the GBE1 p.Y329S variant) result in Adult Polyglucosan Body Disease (APBD) 6 . In these patients, despite the presence of PBs in skeletal muscle, heart and liver, symptoms are limited to the nervous system. In the latter, PBs amass at neuronal axon hillocks and tightly within long axons, which they frequently appear to completely clog. The associated disease consists of upper and lower motor-neuron dysfunction, distal sensory loss, neurogenic bladder and mild cognitive decline 7 .
Since the late 1990's another system has been shown to be essential to the formation of correctly branched glycogen, namely the complex of laforin (EPM2A), a glycogen phosphatase with a carbohydrate-binding domain [8] [9] [10] [11] , and malin (NHLRC1), a RING domain-containing E3 ubiquitin ligase with a growing list of proposed substrates [12] [13] [14] [15] . Deficiency of either laforin or malin leads to the accumulation of highly phosphorylated PBs in many glycogen producing tissues, including the brain.
Unlike in APBD, PBs in LD accumulate not in neuronal long axons but in their cell bodies and dendrites. This is associated not with an axonopathic disease but with a progressive myoclonic epilepsy with death from increasingly intractable seizures usually within a decade of onset 16, 17 .
Most recently, yet another system was implicated, with the absence of the RANBP2-type and C3HC4-type zinc finger containing 1 (RBCK1) protein resulting in the formation of PBs in skeletal and cardiac muscle in both humans and mice [18] [19] [20] . RBCK1 (58 kDa, also known as HOIL-1) is best known to form a ~600 kDa complex with two other proteins, HOIL-1L Interacting Protein (HOIP) and SHANKassociated RH domain-interacting protein (SHARPIN). This complex, LUBAC, mediates M1-linked linear polyubiquitination, a modification that enables nuclear translocation of nuclear factor-B (NF-B) and its pleiotropic immune system-critical transcriptional regulation. Both RBCK1 and HOIP contain a RING-between-RING (RBR) domain. However, the LUBAC-mediated ubiquitination is achieved via HOIP's catalytic domain, with RBCK1's role in the complex seemingly limited to a critical interaction with HOIP's auto-inhibitory domain, preventing the inhibition and allowing HOIP to function 21, 22 . RBCK1 has also been proposed to target a varied set of proteins for ubiquitination and proteasomal degradation potentially through its own RBR domain, independent of LUBAC [23] [24] [25] [26] [27] .
However, most of this evidence was acquired through ex vivo overexpression experiments and remains unsettled.
Patients and mice deficient of RBCK1 have a unique combination of hyper-inflammation and immune deficiency that appears to variably reach clinical significance from none to fatality based on particular pathogen exposure and other factors. Both patients and mice exhibit progressive PB accumulation in skeletal muscle and heart, culminating, in humans, in skeletal myopathy and heart failure 18, 20, 28 .
Here we use an RBCK1 knockout (KO) mouse model to explore the role of RBCK1 in glycogen metabolism and PB formation. Unexpectedly, the brain is the predominantly affected organ, with extensive PB accumulations and neurodegeneration. We compare the brain regional distribution and mechanism of formation of these PBs to those in mouse models of LD (Epm2a -/-) and APBD (Gbe1 Y329S/Y329S ) and find that they parallel, though imperfectly, those of LD.
RESULTS

Distribution of brain PBs in RBCK1 KO mice closely but incompletely overlaps that of LD
Treatment of tissue sections with periodic acid-Schiff diastase (PASD), allows the staining of glycogen-like material that is relatively resistant to amylase (historic: diastase) degradation, such as
PBs 29 . Figure 1 shows the PASD staining of sections from different parts of the brain, spinal cord, skeletal muscle, heart, and liver of wildtype (WT) and RBCK1 KO mice of various ages. There are small levels of PASD stained deposits in the hippocampus of the 14-month-old WT mice, likely corpora amylacea, normally observed in aged humans and mice [30] [31] [32] . While it has been reported that these PBs, stained by PAS, are sensitive to diastase digestion in mouse samples
31
, we still observed them here. All other sections of the WT mouse brain were free from visible polyglucosan accumulation.
Similar to the mouse models of LD (Epm2a -/-; referred to henceforth as laforin KO) 33 and APBD (Gbe1 Y329S/Y329S ; referred to henceforth as GBE1-deficient) [34] [35] [36] , there are significant deposits of PASD stained material in the brains of RBCK1 KO mice, which increase with age ( Figure 1 ). In the hippocampus, there is a higher concentration of PBs in the dendrite-dense stratum lacunosummoleculare in RBCK1 KO mice. The polyglucosan accumulation in the laforin KO mice and GBE1-deficient mice have PBs more evenly distributed throughout the hippocampus (Figure 2 ). The PBs in the RBCK1 KO and laforin KO mice are large in appearance, compared to the smaller ubiquitously spread accumulations in the GBE1-deficient animals.
In the cerebellum (Figure 2 ), laforin KO and RBCK1 KO mice show a high abundance of large PBs throughout the granular layer and the nuclei (dentate, interposed and fastigial), while no evidence of PBs was found in the white matter of the arbor vitae. GBE1-deficient mice, however, have PBs scattered ubiquitously through all areas of the cerebellum, including the arbor vitae.
Another striking difference comparing RBCK1 KO and laforin KO mice with GBE1-deficient mice, is a less consistent accumulation of PBs in the cortex. While in RBCK1 KO and laforin KO there are clusters of PBs, GBE1-deficient mice have small PBs spread ubiquitously throughout the cortex.
Also, while there are clusters of bodies in the thalamus and hypothalamus of RBCK1 KO mice, the PBs were less frequent than in laforin KO and GBE1-deficient mice. Again, the GBE1 deficient mice had a large number of small PBs spread ubiquitously, while the laforin KO and RBCK1 KO mice had
PBs concentrated in specific, dendrite-rich areas.
In the choroid plexus, there appear to be no PBs in RBCK1 KO mice, very few if any in laforin KO mice, and massive accumulations in GBE1-deficient mice. Nearly every cell in the choroid plexus of GBE1 deficient mice appears completely occupied by PBs.
In the spinal cord, PBs are found exclusively in the grey matter in both RBCK1 KO and laforin KO mice, while in GBE1 deficient mice the PBs are scattered ubiquitously throughout both the grey and white matter.
As has previously been described in humans and mice 18, 37, 38 , PBs are seen in the cardiac muscle of RBCK1 KO mice. Compared to human cases, the mouse skeletal muscle contained no significant accumulation of PBs. There were also no bodies in the liver, not inconsistent with human patients, only some of whom have hepatic PB accumulation 18 (Figure 1 and 2).
The glycogen content of brain, skeletal muscle, heart and liver from WT and RBCK1 KO mice was analyzed ( Figure 3A ). Glycogen content was increased in RBCK1 KO, only in the brain. Compared to the WT controls 14-month-old RBCK1 KO mice have on average ~2.6 times higher levels of brain glycogen, consistent with the accumulation of PBs.
Using scanning electron microscopy, RBCK1 KO PBs could only be demonstrated in neurons and not in glia. Within neurons, they were in the cell soma, usually in a juxtanuclear location. PBs could be found anywhere along the neuronal spines. They were completely absent from myelinated long axons but abundantly present at synapses, where they were found both in the dendritic and axonal cytoplasms of synapses ( Figure 3B -E).
Neurodegeneration results in astrocyte activation and astrogliosis 39, 40 . Glial fibrillary acidic protein (GFAP) staining revealed marked astrogliosis. Ionized calcium binding adaptor molecule 1 (Iba1) staining, microglial activation, was also markedly increased in hippocampi and cerebellums of 14-month-old RBCK1 KO mice ( Figure 3F -G). More specifically in the cerebellum, the most dramatic increase in GFAP and Iba1 is detected in the molecular layer and the granular layer of the simple lobule, respectively.
Motor coordination is impaired in RBCK1 KO mice
The physical performance of mice was analyzed using a number of phenotypic tests, including balance beam, grip strength, rotarod, open field, vertical pole and gait analysis. While RBCK1 KO mice showed equal levels of lateral and vertical movement in the open field test compared to controls, and equal levels of forelimb grip strength, they performed significantly poorer on the rotarod, balance beam and vertical pole tests ( Figure 4A ), indicating poor motor coordination. The coordination of these mice was also tested using gait analysis. The gait analysis Regularity Index (RI)
is used to determine a mouse's forelimb-hindlimb coordination while walking 41, 42 . This parameter measures the proportion of sets, each containing four steps that include all four feet. The higher the RI, the more coordinated the walking pattern of the mouse, with a lower RI being indicative of more missteps. As seen in Figure 4A , RBCK1 KO mice have a significantly lower RI compared to WT.
RBCK1 KO impacts learning and memory
Pavlovian fear conditioning was used to analyze aversive learning and memory
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. Mice are placed in a novel chamber and are subject to hearing a tone, while receiving a foot-shock. The mice are then tested the subsequent day to see how they react to being exposed to the same chamber (context fear) and to the same tone in a different chamber (tone fear). The measurement for fear is the amount of time the mouse stays still (freezing) 44, 45 . Importantly, the memory for context and tone represent different brain functions. While damage to the amygdala results in a decrease in the conditioning for both context and tone, lesions of the hippocampus only interfere with the more complex event of the context 46 . As can be seen in Figure 4B , the mean context fear was diminished in the RBCK1 KO mice compared to the controls, with a repeated two-way ANOVA revealing an 
RBCK1 KO mice accumulate abnormal glycogen in the brain
The chain length distribution and phosphorylation at glucosyl carbon 6 (C6) of glycogen from RBCK1 KO and WT brain and muscle tissue is given in Figure 4C . The very limited polyglucosan accumulation in the skeletal muscle of these RBCK1 KO mice (Figure 1 and 3A) is consistent with the chain length distribution and C6 phosphate content being indistinguishable from WT. In the brain however, where there is a large accumulation of PBs, the glycogen has a significantly higher proportion of longer chains than in WT mice and an elevated C6 phosphate content, similar to laforin KO mice 47 .
Glycogen-related enzymes are unaffected by RBCK1 KO
Western blot analyses were performed for a number of the enzymes of glycogen metabolism ( Figure   4D ). Protein levels were indistinguishable between RBCK1 KO and WT muscle and brain with the exception of glycogen synthase (GS) and laforin in the brain ( Figure 4D ). These were increased in the total lysate solely due to their accumulation in the insoluble fraction. . The GS activity ratio and GBE1 activity are given in Figure 4E . GS is regulated by covalent modification (mostly phosphorylation) and allosteric effectors such as glucose 6-phosphate. Measurement of GS activity in the presence of low and saturating concentrations of the allosteric activator glucose 6-phosphate is a measure of the activation state of GS as imposed by GS phosphorylation. The results indicate no change in GS activation as the GS activity ratio in RBCK1 KO brain is very similar to that in WT as well as to those previously published 49 . Branching activity in the brain was measured using a phosphorylase stimulation assay with product separation and visualisation by thin layer chromatography 50
. Despite some variances in the RBCK1 KO group on average the branching activity seems similar to WT. In sum, activities of GS and GBE1, which determine glycogen chain length, are unaltered. The soluble quantities of these enzymes and laforin are also unchanged.
DISCUSSION
The architecture of glycogen molecules is crucial to glycogen solubility and critically includes the regular introduction of branching points. Insufficient branching results in overly long chains that cause glycogen to precipitate and accumulate, which in the brain are associated with neurodegeneration 17
. Until the LD genes were discovered, glycogen architecture was for many decades thought to merely be a function of balanced activities between GS and GBE1. The precise roles of the LD gene products laforin and malin in proper glycogen construction remain unclear. A number of hypotheses are under investigation 14, 17, 51 , including the following with which we consider the preponderance of available knowledge most closely agrees. The laforin-malin complex appears to represent a safety mechanism that is triggered when glycogen chains are overextended. Through laforin's carbohydrate binding module the laforin-malin system is recruited to the region in the glycogen molecule with the elongated chain and inhibits GS in that location through malin-mediated ubiquitination. While the role and origin of the phosphate esters in glycogen are still under investigation, it appears that laforin removes the added phosphate when glycogen chains are reshortened, possibly to allow the chain reshortening, because the glycogen digesting enzyme, glycogen phosphorylase is known not able to digest beyond phosphorylated glucosyl residues 17, 47, 51 .
Recently, RBCK1 was likewise implicated as mice and patients deficient of the protein were shown to accumulate PBs in muscle tissue, in the case of humans resulting in skeletal and cardio-myopathy.
Here we report that in RBCK1 KO mice PBs are much more abundant in brain than in skeletal muscle and heart. The distribution of PBs in the brain closely follows the pattern in LD, which differs from APBD. The PBs are in neurons only, while in APBD they are also in glia 52
. They are in the somatodendritic compartments of neurons and not in myelinated axons, in contrast to APBD where they are primarily in axon hillocks and within myelinated axons 7 . One respect in which they do diverge from PBs of LD is that at synapses PBs are in both axonal and dendritic cytoplasm, while in LD they are only on the dendritic side 53 .
As mentioned, RBCK1's best established function is that of an auxiliary protein within the LUBAC complex, where the actual ubiquitination is carried out by the RBR domain of HOIP. However, RBCK1
also has an RBR domain and may be capable of ubiquitinating substrates independent of LUBAC.
Complete absence of HOIP is incompatible with life based on murine studies The function of RBCK1 (or LUBAC) in glycogen metabolism is likely similar or related to that of the laforin-malin system and dissimilar from that in GBE1 deficiency. Not only are the brain loci of PB formation much more closely aligned between RBCK1 KO and LD mice than between RBCK1 KO and GBE1-deficient mice, but also RBCK1 KO glycogen has the characterstic signature of LD glycogen, namely hyperphosphorylation. Given that RBCK1 and LUBAC share E3 ligase activity with the LD protein malin, the simplest explanation might be that they play a role similar to that of malin, potentially involving regulating GS activity. Like in LD, this regulation would likely occur solely at the few glycogen molecules that develop overextended branches at any one time. This would be consistent with the absence of an effect on overall GS protein and activation state in tissues of the RBCK1 KO mice ( Figure 4D -E) or LD mouse models 49 . PBs in APBD patients and the GBE1-deficient mice result from an ~80% loss of GBE1 activity 6, 56 . GBE1 activity in the RBCK1 KO mice is indistinguishable from that in WT, indicating that RBCK1 deficiency does not cause PBs through an effect on GBE1 activity.
Why PBs remain in the somatodendritic compartment of neurons in LD and RBCK1 KO but seem to travel into and accumulate in long myelinated axons in APBD is unknown. Hyperphosphorylation, the distinguishing feature of LD glycogen, has been suggested as a possible factor 57 , but remains unconfirmed. One remarkable difference between RBCK1 KO and LD PBs is at synapses. While LD PBs are found only in the dendritic side of synapses, RBCK1 KO PBs are present also in the axonal side of synapses. That they appear, like those of LD, not to travel down axons, suggests that in the case of RBCK1 KO they may form locally in axonal termini, and that RBCK1 may therefore have a glycogenrelated role in this location that the LD proteins do not.
Patients with RBCK1 mutations have a hyperinflammation/immune-deficiency disease that ranges from no clinical symptoms to fatality 18, 20, 28 . . All patients with RBCK1 mutations have the glycogen storage disease and succumb from it to cardiac failure, unless transplanted 18, 60 . To date, this newly recognized glycogen storage disease has not been associated with a brain phenotype. It is possible that RBCK1 is less relevant in human compared to mouse brain glycogen metabolism. Alternatively, now cardiac-transplanted RBCK1-deficient patients may yet develop neurological disease.
In conclusion, this data is indicative of a new layer of regulation of glycogen metabolism. The similarities with LD and differences from APBD, together with absence of any alteration of branching enzyme, suggests that this system intersects or parallels that of laforin-malin. Future work, now on both the laforin-malin and the RBCK1 tracks, should elucidate the basic mechanisms of proper threedimensional construction of the glycogen molecule.
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Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Berge A. Minassian (Berge.Minassian@utsouthwestern.edu). Mice were sacrificed by cervical dislocation and harvested brain, skeletal muscle, heart and liver tissues were divided with half being fixed in neutral buffered formalin (10%) and half being snap frozen in liquid nitrogen. Spinal cords were removed and fixed in neutral buffered formalin. RBCK1
EXPERIMENTAL MODEL AND SUBJECT DETAILS Animals
mice were sacrificed at 1 month, 6 months and 14 months. and laforin and GBE1 mice were sacrificed at 12-14 months.
All animal procedures were approved by The Centre for Phenogenomics Animal Care Committee.
METHOD DETAILS Histochemistry
Samples were stained with the following: periodic acid-Schiff staining with diastase predigestion (PASD) was used to stain polyglucosan bodies; glial fibrillary acidic protein (GFAP, rabbit polyclonal anti-GFAP, BioLegend) staining and ionized calcium binding adaptor molecule 1 (Iba1, rabbit polyclonal anti-Iba1, Wako Chemicals) staining were used to assess gliosis.
Scanning electron microscopy
As previously described 33 , mice were perfused with 2.5% glutaraldehyde in 0.1 M phosphate buffer (pH 7.4) through the heart's left ventricle. After mincing into ~1 mm cubes the samples were left to fix for 4 h. The tissue was washed with phosphate buffer and post fixed in 2% OsO 4 (in phosphate buffer) for 1 h. The tissue was dehydrated in an ascending series of acetone concentrations and were infiltrated, embedded and polymerized in Embed 812-Araldite overnight at 60 °C. Ultrathin slices were cut and stained with uranyl acetate and lead citrate. Scanning electron microscopy was then used to analyze the sections (JEOL JEM 1011, Peabody, MA).
Behavioural testing
All mice were acclimatized to the behavioural testing room for 30 min prior to testing.
Rotarod
An accelerating rotarod (4 -40 rpm over 300 s) was used to assess motor coordination. Latency to fall or to complete two passive rotations was measured. Each mouse performed four trials with a 30 min inter-trial interval. The longest three of four scores were averaged.
Vertical pole
The vertical pole test was performed as previously described 63, 64 . Mice were placed on top of a rough-surfaced vertical pole (45 cm high, 1.1 cm in diameter). The time for each mouse to turn downward (t 1 ) and the total time to reach the floor (t 2 ) were recorded (t 2 cut-off limit being set to 120 s). Each mouse performed three trials. The difference between t 2 and t 1 was averaged across the trials.
Balance beam
The time taken for mice to traverse a round balance beam (90 cm long, 18 mm in diameter) suspended 50 cm above the floor was recorded (cut-off limit set to 60 s). Mice underwent four consecutive training trials the day prior to testing.
Grip strength
Maximum forelimb grip strength (peak tension) was measured using the Animal Grip Strength System (San Diego Instruments). Mice underwent five consecutive trials and all scores were averaged.
Gait analysis
The ExerGait (XL) treadmill (Columbus Instruments) was used to analyze mouse gait. The treadmill speed was set to 19 cm/s and the camera frame rate was set to 100 frames/s with a maximum of 2000 frames taken. Mice were placed onto the non-moving treadmill for 30 s to acclimatize.
Recording commenced once the treadmill was turned on and mice reached a constant running pace.
The test duration was 20 s, however, if the mouse's running pace oscillated, the procedure was restarted. The collected video was analyzed using TreadScan software (Clever Sys Inc.).
Fear conditioning
The use of Pavlovian fear conditioning is widely used to analyze aversive learning and memory
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. This method involved exposure to a neutral conditional stimulus (tone), paired with a fear-inducing aversive unconditional stimulus (foot shock); all performed in a novel chamber. After this pairing, the amount of fear exhibited by a mouse, measured as the percentage of time the mouse does not move (freezing percentage), when exposed again to the chamber (contextual fear) and to the tone (cued fear), is indicative of the mouse's memory. The link between freezing and fear in rodents has been long established 44, 45 .
Using an NIR Video Fear Conditioning System for Mouse (Med Associates Inc.), video freeze software was used to score the freezing and movement of mice. Mice were first placed into the novel chamber for 120 s (giving a baseline freezing percentage). This was followed by 30 s of audible tone and 2 s of foot shock (co-terminating with the tone) and then followed by 150 s with no stimuli.
After 24 h mice were returned to the same chamber and freezing was recorded for 300 s. This was used to determine the contextual fear (their memory of the environment and of the shock they received the previous day). After 2 h the mice were then placed back in the chamber for 120 s without any stimulus and then 180 s with a second presentation of the tone, measuring the cued fear, again expressed as the percentage of the time when mice froze
Open field test
The open field test is used to test for anxiety and exploratory behaviour. 
Glycogen extraction
Glycogen was extracted and quantified using a similar procedure to that previously described 65 .
Briefly, frozen tissue from brain, skeletal muscle, heart and liver was ground and boiled in 30% [w/v] KOH for 1 h, followed by ethanol precipitation (67% [v/v] , 15 mM LiCl) for a minimum of 1 h at -30 °C. Samples were centrifuged at 16 000 g for 20 min at 4 °C, with the supernatants being discarded.
The pellets were resolubilized in water by heating samples to 95 °C for 10 min, using intermittent agitation. Ethanol precipitation was repeated three more times, with the final pellet being redissolved in water. Brain glycogen was further purified in order to accurately quantify the C6 phosphate content and the chain length distribution 47 .
Glycogen content measurements
Glycogen was degraded to glucose using amyloglucosidase using a method similar to that performed showing background glucose not coming from glycogen was insignificant and could thus be discounted.
Chain length distributions
As previously performed 47 , extracted brain and skeletal muscle glycogen (purified further as outlined above) was debranched using isoamylase. Glycogen (10-20 g) was incubated at 37 °C overnight with 200 U of isoamylase (Sigma), in 110 L of 10 mM sodium acetate (pH 5). After incubation the samples were heated at 95 °C for 10 min to inactivate the isoamylase and centrifuged at 20 000 g for 10 min at room temperature. A 90 l aliquot of the supernatant was applied to a High Performance Anion Exchange Chromatography with Pulsed Amperometric Detection (HPAEC-PAD) system (ThermoFisher, ICS5000). The debranched glycogen chains were separated using a CarboPac PA100 column and guard combination (ThermoFisher) at a constant flow rate of 1 mL/min. The two eluents A (150 mm NaOH) and B (150 mM NaOH, 500 mM sodium acetate) were combined for the following elution profile: 15 min equilibration using 95% [v/v] A, 5% [v/v] B; after injection 5 min 95% A, 5% B; a 9 min linear gradient to 70% A, 30% B; 9 min linear gradient to 55% A, 45% B; 37 min linear gradient to 33% A, 67% B; finally 10 min of 100% B. The resultant chromatograms were analyzed using the Dionex Chromeleon Software (V7.2). The relative peak areas were determined for each chain length, with the four replicates being averaged.
C6 phosphate analysis
The amount of covalently attached phosphate at the C6 position in the glucose monomers was measured using a method previously described 68 . Briefly, brain and skeletal muscle preparations (see above) were hydrolyzed in 0.7 M HCl for 3h at 95 °C, followed by neutralization with 5 M KOH. The levels of G6P were determined using an enzymatically cycling assay 68 , using authentic G6P as an external standard. The levels of G6P were normalized to the hydrosylate's glucose content determined as previously described
67
.
Western blot analysis
Western blot analysis for various proteins was completed essentially as described previously 29 .
Briefly, protein concentration was determined and 20 g of total protein was loaded and separated on a 10% SDS-PAGE. Proteins were transferred to nitrocellulose membranes, blocked with a 5% solution of non-fat dry milk powder. Subsequently, the membrane was probed with commercial primary antibodies. The antibodies used were glycogen synthase rabbit monoclonal antibody (15B1;
Cell Signalling), GBE1 mouse polyclonal antibody (B01P) and laforin monoclonal antibody (M02, clone 6C6; Abnova), glycogen phosphorylase mouse monoclonal antibody (9F5) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH; Santa Cruz Biotechnology), GSK3/ mouse monoclonal antibody (ThermoFisher Scientific), actin mouse monoclonal antibody (BD Transduction Laboratories). The membrane was further blotted with secondary antibodies conjugated with horseradish peroxidase. Proteins were visualized using a chemiluminscent detection kit (BIO-RAD).
In vitro glycogen synthase activity assay 
In vitro GBE1 activity assay
The activity of GBE1 was assayed using a previously described procedure 50 . A 50 L reaction mixture was prepared containing 2.2 U of phosphorylase a, 1 mM AMP, 0.5 M sodium citrate, 50 mM of -D-
]-glucose-1-phosphate (specific activity of ~300 dpm/nmol) and 15 L of brain lysate (normalized to 1 mg mL -1 protein) . The phosphorylase a was added last to initiate the reaction and 1 L aliquots were quenched at 0, 15 and 30 min by loading onto aluminium TLC plates (silica gel 60, Merck). The TLC plates were left at room temperature to dry. The separation of residual glucose-1-phosphate (G-1-P) from those incorporated into the growing polymer was achieved by linear ascending development for ~3 h in 3:12:4:4 n-butanol:isopropanol:acetic acid (glacial):H 2 O. After the TLC plates had dried they were developed overnight and the radioactivity was determined. The amount of G-1-P incorporated into the glucose polymer, which remained at the bottom of the TLC plate was then calculated as a % of total G-1-P signal.
QUANTFICATION AND STATISTICAL ANALYSIS
Normality of data were assessed using the Shapiro-Wilk test. 
